Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...

As the cost Mounjaro jabs is set to increase by as much as 170 per cent, Jade Kay, who has already spent £2.4k on the drug, ...